Itau Unibanco Holding S.A.’s CytomX Therapeutics CTMX Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-756	Closed	-$8K	–	901
2019 Q3	$8K	Hold	756	–	–	﹤0.01%	286
2019 Q2	$8K	Sell	756 -650	-46%	-$6.81K	﹤0.01%	590
2019 Q1	$21K	Hold	1,406	–	–	﹤0.01%	562
2018 Q4	$21K	Buy	+1,406	New	+$20.9K	﹤0.01%	562

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Itau Unibanco Holding S.A.'s CTMX Position: Q4 2019 in Review

Itau Unibanco Holding S.A. sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 756 shares — an estimated $8K sold.

Itau Unibanco Holding S.A. first reported a position in CTMX in Q4 2018 and held it in 4 quarters. The position peaked at $21K in Q1 2019. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

Itau Unibanco Holding S.A. reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 756 CytomX Therapeutics shares in Q4 2019, an estimated $8K.
Itau Unibanco Holding S.A. first reported a position in CytomX Therapeutics in Q4 2018 and held it in 4 quarters.
Itau Unibanco Holding S.A.'s CytomX Therapeutics position peaked at $21K in Q1 2019.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q4 2019, filed 14 Feb 2020.